Stockscreener 앱 받기
27.54
1.04%
-0.29
Ultragenyx Pharmaceutical Inc 주식(RARE)의 최신 뉴스
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace
Cantor Fitzgerald Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $105.00 - MarketBeat
Reversal indicators forming on Ultragenyx Pharmaceutical Inc. stockWeekly Growth Portfolio Performance Summary - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - FinancialContent
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call Transcript - MSN
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser
Signal strength of Ultragenyx Pharmaceutical Inc. stock in tech scannersHigh Conviction Stock Long-Term Summary - Newser
Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionFree Weekly Setup With 3x Return Potential - Newser
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - uk.finance.yahoo.com
Ultragenyx Pharmaceutical Analyst Ratings: Recent Assessments and Insights - AInvest
What makes Ultragenyx Pharmaceutical Inc. stock price move sharplyEquity Portfolio Outlook and Performance Summary - Newser
FDA requests manufacturing changes for UX111 gene therapy - Sanfilippo Syndrome News
Ultragenyx Bets On Growth With Bullish Analyst Backing - Finimize
Ultragenyx Pharmaceutical Q2 2025 Earnings: Revenue Beats Expectations, Loss Narrows - AInvest
Ultragenyx Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
‘Urgent need’ for treatment drives GTX-102 study enrollment - Angelman Syndrome News
Ultragenyx Pharmaceutical Inc. stock momentum explainedFree Proven Entry Plan With Low Risk Trade - Newser
Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges - TipRanks
‘On track to become profitable’: Marin County rare disorder drug maker narrows loss in Q2 - The North Bay Business Journal
S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas - insights.citeline.com
Ultragenyx (RARE) Q2 Revenue Up 13% - Nasdaq
Ultragenyx Pharmaceutical Inc. SEC 10-Q Report - TradingView
Ultragenyx Pharmaceutical Q2 2025 Earnings Call Transcript - MarketBeat
Ultragenyx outlines $640M–$670M 2025 revenue target as clinical milestones advance - MSN
Ultragenyx: Q2 Earnings Snapshot - New Haven Register
Price action breakdown for Ultragenyx Pharmaceutical Inc.Long Term Equity Screener with Safety Metrics - Newser
Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Ultragenyx Pharmaceuticals: A High-Stakes Play in Rare Disease Gene Therapy - AInvest
Ultragenyx's Q2 2025 Earnings Call: Dissecting Contradictions on Setrusumab Efficacy, FDA Interactions, and Resubmission Strategy - AInvest
Ultragenyx Pharmaceutical Q2 2025 Earnings Call Transcript: Financial Results and Business Update - AInvest
Ultragenyx Sets 2025 Revenue Target at $640M-$670M Amid Clinical Advancements - AInvest
Ultragenyx Reports Growth Amidst Strategic Advancements - TipRanks
Earnings call transcript: Ultragenyx Q2 2025 beats EPS forecast, stock rises - Investing.com
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - sg.finance.yahoo.com
Ultragenyx Reports Better-Than-Expected Q2 Loss and RevenueNews and Statistics - IndexBox
Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ultragenyx August 2025 slides: Pipeline advances toward approvals as revenue grows By Investing.com - Investing.com South Africa
RENEW 8-K: Ninth SPAC Extension Adds $250k to Trust, Deadline Sep 5 2025 | RARE SEC FilingForm 8-K - Stock Titan
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update - GlobeNewswire
ATTENTION RARE Shareholders: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
How hedge fund analytics apply to Ultragenyx Pharmaceutical Inc. stockLow Risk Stock Selection Strategy Guide - Newser
Visual trend scoring systems applied to Ultragenyx Pharmaceutical Inc.RSI and MACD Signal Summary with Trends - Newser
Ultragenyx Pharmaceutical Earnings Report: Analysts Expect $-1.31 EPS, Shares Down 42.98% Over Last Year - AInvest
Ultragenyx Pharmaceutical's Promising Outlook: Buy Rating Reiterated Amidst Aspire Study Progress - AInvest
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory - Insider Monkey
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome - MSN
What to Expect From Ultragenyx Pharmaceutical's Earnings - 富途牛牛
0.24%
3.39%
자본화:
|
볼륨(24시간):